

Australian Government

IP Australia

AUSTRALIAN OFFICIAL JOURNAL

OF

PATENTS

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

10 February 2011

Contents

General	Inform	nation	R. I	Notices

Alteration Of Name In Register	14
Amendments, Section 104 Amendments Made	12
Assignments Registered	12
Change of Name(s) of Applicant(s), Section 104	12

General Information

For Information on the following please see our website <u>www.ipaustralia.gov.au</u> or contact our Customer Service Network on 1300651010

Editorial enquiries
Contact information
Freedom of Information ACT
Professional Standards Board
Sales
Requests for Information under Section 194 (c)
Country Codes
Trade Mark and Designs Hearing Sessions
INID (Internationally agreed Numbers for the Indentification of Data)

GUIDE TO THE USE OF THIS JOURNAL

The Australian Official Journal of Patents (AOJP) reports all major events and actions which take place during the life cycle of an Australian patent and provides certain details of these actions as they relate to the patent or patent application involved. This guide sets out to teach the reader how to use the journal to access this information.

While there are many possible actions in the life of a patent, the majority of actions reported relate to the following events, which are the main stages in the progression of a patent application to a sealed patent:

(i) FILING -

This is the act of making an application. When the application is first filed certain details are published.

(ii) OPEN-TO-PUBLIC-INSPECTION (OPI) -

Approximately 18 months after first filing of an Australian or a corresponding foreign application, certain application documents, including the complete specification, become available to the public (Open-to-Public-Inspection or "OPI"). Relevant application details are published.

(iii) ACCEPTANCE -

This is the Commissioner's acceptance of a patent application. Once the Commissioner has accepted a patent application, certain details of the application are published in the AOJP. Notice of opposition may be filed within three months of advertisement of acceptance.

(iv) OPPOSITION -

If an opposition action is commenced against the grant of the patent, the six-figure acceptance number and the name of the opponent are published. If the opposition is to the Certification of an Innovation Patent, the patent number and the name of the opponent are published.

(v) SEALING -

Most accepted applications are not opposed. These proceed to sealing and become granted patents. Of the few that are opposed (less than 1%) most of these, after resolution of the opposition, proceed to sealing and become granted patents. Sealed patents are simply listed in order of their application number.

(vi) CERTIFICATION

This is the Commissioner's Certification after passing examination of a previously granted unexamined Innovation Patent.

In addition to the actions related to these stages, other actions reported include: assignments, lapsing or withdrawal of applications and ceasing or expiry of patents, voluntary amendments, extensions of time for certain actions and registration of licences.

How To Identify Information Using "INID" Numbers

Patents are published in many different countries and in many different languages. As a result, finding the information that you want (eg the filing date) on a patent document or in a journal can be quite difficult. There is an international system operating, however, which codifies this information in an unambiguous way, by assigning a specific number to each piece of information about the history of a patent. These numbers are called the **Internationally agreed Numbers for the Identification of Data** or INID numbers.

These numbers appear on all published patents and abstracts and are used throughout this journal to identify particular items of information. For example, the date on which a document is filed has the INID number (22), while the name of the applicant has the INID number of (71). These numbers are always expressed in parentheses and always immediately precede the information to which they relate. For example:

(22) 12.10.91

means that the filing date of the document which contains this reference is 12 October 1991. Learning the INID numbers for the information you want will help you find it quickly and easily.

A complete list of the INID numbers and the items to which they relate is provided at the end of this Guide.

How Australian Patent Documents are Numbered

Patent applications in Australia are assigned a number at the filing stage in their processing. Each Australian application will retain the same number throughout its life, though different numbers may be associated to the application. The number will incorporate the year of lodgment then a unique number within the appropriate range.

There will be number ranges for types of patents:

100,000 – 199,999 Innovation

200,000 - 799,999 Standard

800,000 - 899,999 Petty

900,000 - 999,999 Provisional

When searching for information and ordering documents it is vital that you understand the numbering systems.

1. Provisional Applications are given a ten-figure number

e.g. 2002901123

A provisional application number is identified by the INID number (21).

2. Complete and Innovation Applications are also given a ten-figure application number

e.g. 2002200345 Standard

2002100123 Innovation

There are prefixes applied to this number which indicate whether the application has been accepted:

A document corresponding to an unaccepted application has the prefix, AU-A; eg AU-A-2002200234. A document corresponding to an accepted application carries the prefix AU-B; eg AU-B-2002200234.

Users need to be aware that an accepted document may differ from the corresponding unaccepted document. This is because amendment may occur between first publication (OPI) and second publication (acceptance).

A ten-figure application number is identified by the INID number (21).

NOTE: When ordering any patent document from us, whether accepted or not, please quote the ten-figure application number preceded by the appropriate prefix.

Arrangement of Information in the Journal

For each of the categories

- (i) Provisional Applications Filed,
- (ii) Complete Applications Filed,
- iii) Applications Open to Public Inspection
- (iv) Applications Entered National Phase
- (v) Applications Accepted, and
- (vi) Innovation Patent Certified.

The Journal lists the information published in that category in an alphabetical Name Index list based on the name of the applicant. These indices are useful if you wish to find information about applications made by a particular applicant.

In addition to the Name Index there is provided, for each of these categories, a Numerical Index This index lists the applications either in order of their five-figure Application Numbers, in the case of complete applications filed and applications OPI, or in order of their six-figure Document Number in the case of accepted applications. It provides, for each number, the name of the applicant. These indices are useful if you wish to track the progress of a particular patent application.

There are also IPC Indices provided for applications which are OPI and for applications which have been accepted. IPC stands for International Patent Classification. Each IPC "mark" is an alpha-numerical representation of a particular area of technology. These indices are in order of IPC mark, and within each mark provide either the five-figure application numbers of the application which are now OPI or the six-figure numbers of the cases now accepted. These indices are useful if you wish to check on patent activity in a particular technology.

Using the Indices

1. To Find Patent Information if You Know the Name of the Applicant.

Use the Name Indices. They will give you the following information identified by their INID number:

<u>ITEM</u>	<u>INID</u> No.	<u>ITEM</u>	<u>INID</u> No.
A) Provisional applications filed - Name Ind The name of the applicant The Provisional application number The date of filing The title of the invention	(71) (21) (22) (54)	B) Complete applications filed - Name Inde The <u>name</u> of the applicant The <u>number</u> assigned to the application The <u>date</u> of filing <u>Title</u> of the invention <u>Number</u> of priority document(s) if any <u>Date(s)</u> of filing of priority documents <u>Country</u> of which priority documents filed PCT application <u>number</u>	(71) (21) (22) (54) (31) (32) (33) (86)
<u>ITEM</u>	<u>INID</u> No.	<u>ITEM</u>	<u>INID</u> No.
C) Applications open to public inspection - Name Index		D) Applications accepted - Name Index	
The name of the applicant The number of the document The number assigned to the application The date of filing The title The classification marks Priority document number(s) Date of filing of priority document (s) Country in which priority document filed Publication date of unexamined document Inventors names if known Patent Attorneys	(71) (11) (21) (22) (54) (51) (31) (32) (33) (43) (72) (74)	The <u>name</u> of the applicant The <u>number</u> of the document The <u>number</u> of the accepted document The <u>number</u> assigned to the application The <u>date</u> of filing The <u>title</u> The <u>classification marks</u> PCT publication <u>number</u> Priority document <u>number</u> Date of filing of priority document(s) Country in which priority document filed Publication <u>date</u> of unexamined document	(71) (11) (10) (21) (22) (54) (51) (87) (31) (32) (33) (43)
<u>ITEM</u>	<u>INID</u> No.		
E) Patents Certified – Name Index The <u>name</u> of the applicant The <u>number</u> of the accepted document The <u>number</u> assigned to the application The <u>date</u> of filing The <u>title</u> The <u>classification marks</u> Priority document <u>number</u> <u>Date</u> of filing of priority document(s) <u>Country</u> in which priority document filed Publication <u>date</u> of granted patent Inventors <u>names</u> <u>Patent Attorneys</u> Related by division	(71) (10) (21) (22) (54) (51) (31) (32) (33) (45) (72) (74) (62)		

You will notice at each stage of following application through that all applications are in alphabetical order of Applicant, not inventor.

2. To Find Information About a Patent Application if You Know its Number.

Use the appropriate numerical index. This will give you the name of the applicant from the number. You will then need to use the appropriate Name Index as above to find out other information about the Patent Application you are interested in.

The following Numerical Indices are available:

- A) Provisional Applications filed.
- B) Complete Applications filed.
- C) Innovation Applications filed.
- D) Applications Open to Public Inspection.
- E) Applications Accepted.
- F) Innovation Patent Certified

3. To Find Information About Patent Documents in the Area of Technology in which You are Interested if You Know the International Patent Classification Mark for that Area.

All patent applications are classified according to their subject matter using the International Patent Classification (IPC). Although the system is very detailed and covers all technologies, knowledge of the IPC marks of the technologies you are interested in will allow you to find patent documents in these technologies guite easily.

The indices to use are

- A) Applications OPI IPC Index
- B) Applications accepted IPC Index.

These indices give you the numbers of the applications which are either OPI or Accepted and are listed in order of their IPC marks.

Once you have the numbers of the documents that interest you, consult the relevant Number Index (see 2. above) to find the applicant's name, and then the Name Index (see 1. above) to find out the details of that application.

'INID' NUMBERS in use on Australian Patent Documents

'INID' is an acronym for 'Internationally agreed **N**umbers for the Identification of **D**ata'.

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s).
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s)
- (32) Date(s) of filing priority application(s)
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of an unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant or certification has taken place on or before the said date.

(50) Technical Information

- (51) International Patent Classification
- (52) Domestic or national classification

- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text
- (57) Abstract or claim

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document

- (71) Name(s) of applicant(s)
- (72) Name(s) of inventor(s) if know to be such
- (74) Name(s) of attorney(s) or agent(s)
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number (87) PCT Publication Number

NOTE

(1) Australian patent documents published on or after 26 October 1978 should be referred to by the application number preceded by the prefix AU-A or AU-B.

AU-A = Pre-examination

AU-B = Post-examination

- (2) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (3) INID code 74 provides for the name of the patent attorney, or firm of attorneys, prosecuting an application.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Senomyx, Inc. [2011] APO 05

Patent Application: 2008200999

Title: Use of specific T2R taste receptors to identify compounds that block bitter taste

Patent Applicant: Senomyx, Inc.

Delegate: Dr S.D.Barker

Decision Date: 2 February 2011

Catchwords: PATENTS – examiner objection – lack of unity – case management of divisional

applications - no response by applicant - application refused

Representation: Patent applicant: Davies Collison Cave

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Qualcomm Incorporated [2011] APO 06

Patent Application: 2009251132

Title: Method and apparatus for multiplexing high-speed packet data transmission with

voice/data transmission

Patent Applicant: Qualcomm Incorporated

Delegate: Dr S.D.Barker

Decision Date: 2 February 2011

Catchwords: PATENTS – examiner objection – novelty and inventive step – case

management of divisional applications – no response by applicant – application

refused

Representation: Patent applicant: Madderns Patent & Trade Mark Attorneys

Proceedings under the Patents Act 1990

Change of Name(s) of Applicant(s), Section 104

PL3423 Brian Timothy Boland The name of the applicant(s) has been changed to **Helen Jane Boland**

PL8491 Brian Timothy Boland The name of the applicant(s) has been changed to **Helen Jane Boland**

PM9158 Brian Timothy Boland The name of the applicant(s) has been changed to **Helen Jane Boland**

PR1255 Brian Timothy Boland The name of the applicant(s) has been changed to **Helen Jane Boland**

PR4654 Brian Timothy Boland The name of the applicant(s) has been changed to **Helen Jane Boland**

1994

81738 Brian Timothy Boland The name of the applicant(s) has been changed to ${\bf Helen\ Jane\ Boland}$

Amendments, Section 104

Amendments Made

676722 **Children's Medical Center Corp.** The nature of the amendment is as was notified in the Official Journal dated 29 Jul 2010

676722 **Children's Medical Center Corp.** The nature of the amendment is as was notified in the Official Journal dated 5 Aug 2010

744779 Lucite International UK Ltd. The nature of the amendment is as was notified in the Official Journal dated 26 Aug 2010

769955 **Yahoo! Inc.** The nature of the amendment is as was notified in the Official Journal dated 5 Aug 2010

773268 University of Medicine and Dentistry of New Jersey The nature of the amendment is as was notified in the Official Journal dated 15 Jul 2010

780010 Commonwealth Scientific and Industrial Research Organisation The nature of the amendment is as was notified in the Official Journal dated 15 Jul 2010

Assignments Registered

650163 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
650195 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
651298 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
652488 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
653689 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
658402 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
660850 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
662679 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
669037 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
669087 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
669301 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
670523 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
671040 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
671383 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
673221 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
673490 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
674420 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
675868 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
677899 Mobility ,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola
678045 Mobility,	Motorola, Inc.	Inc.	The	patent	has	been	assigned	to	Motorola

678124 Motorola, Inc. The patent has been assigned to Motorola

Mobility, Inc.

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

Assignments	Registered	-	cont'd

678741 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
681053 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
681446 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
683730 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
686046 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
686279 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
686927 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
689180 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
689403 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
689588 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
691111 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
692628 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
692737 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
696122 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
696985 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
702666 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
702964 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
707303 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
709770 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
712503 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
713966 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
714193 Motorola, Inc. The patent has been assigned to Motorola Mobility , Inc.
718572 Motorola, Inc. The patent has been assigned to Motorola

Assignments Registered - cont'd

Mobility, Inc.

719164 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

724170 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

726551 Motorola, Inc. The patent has been assigned to **Motorola Mobility**, Inc.

732494 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

733108 Motorola, Inc. The patent has been assigned to **Motorola Mobility**, Inc.

733259 Motorola, Inc. The patent has been assigned to ${\bf Motorola}$ ${\bf Mobility,\,Inc.}$

734151 Motorola, Inc. The patent has been assigned to **Motorola Mobility**, Inc.

734780 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

735531 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

739254 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

740187 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

742143 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

750290 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

 $750357\,$ Motorola, Inc. The patent has been assigned to Motorola Mobility, Inc.

756506 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

760945 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

768927 Motorola, Inc. The patent has been assigned to ${\bf Motorola}$ ${\bf Mobility},$ Inc.

771229 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

772738 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

776836 BP Refining & Petrochemicals GmbH The patent has been assigned to ${\bf BP}$ Europa ${\bf SE}$

779918 Motorola, Inc. The patent has been assigned to **Motorola Mobility, Inc.**

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

Alteration Of Name In Register

657863 Brian Timothy Boland The name of the patentee(s) has been changed to **Helen Jane Boland**

671949 Facet Biotech Corporation The name of the patentee(s) has been changed to **Abbott Biotherapeutics Corp.**

696672 Mallinckrodt Baker, Inc The name of the patentee(s) has been changed to **Avantor Performance Materials, Inc.**

716538 Brian Timothy Boland The name of the patentee(s) has been changed to **Helen Jane Boland**

725821 Fred Hutchinson Cancer Research Center; Facet Biotech Corporation The name of the patentee(s) has been changed to Fred Hutchinson Cancer Research Center; Abbott Biotherapeutics Corp.

764211 Facet Biotech Corporation The name of the patentee(s) has been changed to **Abbott Biotherapeutics Corp.**

778241 CGG Marine The name of the patentee(s) has been changed to ${f CGGVeritas}$ Services ${f SA}$

780843 $\,$ Adze Pty Ltd $\,$ The name of the patentee(s) has been changed to Eziadz Pty Ltd

Notice of Intention to Amend pursuant to Order 58 Rule 10(1) of the Federal Court Rules

Australian Patent 666859 in the name of Aventis Pharma S.A.

Section 105 Patents Act 1990 (Cth)

Advertisement pursuant to Order 58, Rule 10(1) of the Federal Court Rules 1979

Identity of proceedings in which application will be made:

Federal Court of Australia
New South Wales District Registry
General Division
NSD 1373 of 2010 and NSD 1521 of 2010

Parties to NSD 1373 of 2010 proceedings:

Interpharma Pty Ltd (First Applicant; First Cross-Respondent)
Aventis Pharma S.A. (First Respondent; First Cross-Claimant)
May & Baker Limited (Second Respondent; Second Cross-Claimant)
Sanofi Aventis Australia Pty Ltd (ACN 008 558 807) (Third Respondent; Third Cross-Claimant)

Parties to NSD 1521 of 2010 proceedings:

Hospira Australia Pty Ltd (First Applicant; First Cross-Respondent)
Hospira Pty Ltd (Second Applicant; Second Cross-Respondent)
Aventis Pharma S.A. (First Respondent; First Cross-Claimant)
May & Baker Limited (Second Respondent; Second Cross-Claimant)
Sanofi Aventis Australia Pty Ltd (ACN 008 558 807) (Third Respondent; Third Cross-Claimant)

Particulars of amendments sought:

Aventis Pharma S.A., the registered proprietor of Australian Patent No 666859 (the *Patent*), will seek an Order under Section 105(1) of the *Patents Act 1990* (Cth) directing the amendment of the Patent as follows:

Cancel existing pages 12 and 13 and substitute therefor new pages 12 to 14 enclosed

A marked-up copy of existing pages 12 and 13 indicating the nature and location of the proposed amendments is enclosed.

Address for service for party seeking amendment:

Allens Arthur Robinson
Deutsche Bank Place
Corner Hunter and Phillip Streets
Sydney NSW 2000

Attention: Philip Kerr

Any person intending to oppose the application who is not a party to the proceedings must, not later than 28 days after publication of this advertisement, give written notice of that intention to the Commissioner and to the persons who are parties to the proceedings.

The claims defining the invention are as follows:

15

20

25

 A composition suitable for injection comprising a water-insoluble taxane derivative of formula (I)

- in which R represents a hydrogen atom and R_1 represents a tert-butoxycarbonylamino radical, dissolved in a surfactant which is a polysorbate, and containing less than 5% by volume of ethanol.
- A composition according to claim 1, being a stock solution containing less than 5% by
 volume of ethanol.
 - 3. A composition according to claim 2, containing less than 2% by volume of ethanol.
 - 4. A composition according to claim 2, containing less than 1% by volume of ethanol.
 - 5. A composition according to claim 1, being a perfusion solution containing less than 2% by volume of ethanol.
 - 6. A composition according to claim 5, containing less than 1% by volume of ethanol.
 - 7. A composition according to claim 5, containing less than 0.1% by volume of ethanol.
 - 8. A composition according to any one of claims 5 to 7, which is physically stable for at least 8 hours at room temperature.
 - 9. A composition according to any one of claims 2 to 4, containing up to 200 mg/ml of the compound of formula (I).

- A composition according to any one of claims 2 to 4, containing up to 80 mg/ml of the compound of formula (I).
- 11. A composition according to any one of claims 2 to 4, containing 20 to 80 mg/ml of the compound of formula (I).
 - 12. A composition according to any one of claims 5 to 8, containing up to 1.0 mg/ml of the compound of formula (I).
- 13. A composition according to any one of claims 5 to 8, containing up to 0.5 mg/ml of the compound of formula (I).
 - 14. A composition according to any one of claims 5 to 8, containing up to 0.3 mg/ml of the compound of formula (I).
 - 15. A composition according to any one of claims 5 to 8, containing up to 0.1 mg/ml of the compound of formula (I).
- 16. A composition according to any one of claims 1 to 15, wherein the polysorbate is polysorbate 80.

15

30

- 17. A composition according to any one of claims 5 to 8 or 12 to 16, containing no more than 1.16 %vol of polysorbate.
- 25 18. A composition according to any one of claims 5 to 8 or 12 to 16, containing from 0.15 to 0.69 %vol of polysorbate.
 - 19. A method for preparing a composition according to any one of claims 2 to 4 or 9 to 11, wherein the compound of formula (I) is solubilised in ethanol, the surfactant is added and the ethanol is then evaporated off.

- 20. A method for preparing a composition according to any one of claims 2 to 4 or 9 to 11, wherein the composition is prepared by slow addition of the compound of formula (I) to a solution of the surfactant containing 1 to 2% ethanol.
- 5 21. A perfusion solution containing less than 0.5 mg/ml of the compound of formula (I) as defined in claim 1, less than 1 ml/l of ethanol, and less than 15 ml/l of a surfactant which is a polysorbate.
- 22. The perfusion solution according to claim 21, containing 0.1 to 0.3 mg/ml of the compound of formula (I).

The claims defining the invention are as follows:

A cCompositions suitable for injection comprising a water-insoluble taxane derivative of formula (I)

5

in which R represents a hydrogen atom and R₁ represents a tert-butoxycarbonylamino radical, dissolved in a surfactant chosen from which is a polysorbates, polyoxyethylene glycol esters, and esters of polyoxyethylene castor oil derivatives, and containing less than 5% by volume of ethanol.

10

- A composition according to claim 1, being a stock solution containing less than 5% by volume of ethanol.
- 23. A cCompositions according to claim 12, characterized in that they containing less than 2%
 by volume of ethanol.
 - 3. Compositions according to claim 1 or 2 based on a derivative of formula (I)

20

in which R represents a hydrogen atom or an acetyl radical and the symbol R₄ represents a tert-butoxycarbonylamino or benzoylamino radical.

4. Compositions according to claim 3, characterized in that, in the compound of formula (I), R represents hydrogen and R₄-a tert-butoxycarbonylamino radical.

- 5. Compositions according to claim 3, characterized in that, in the compound of formula (I), R represents an acetyl group and R₁ represents a benzoylamino radical.
- 5 4. A composition according to claim 2, containing less than 1% by volume of ethanol.
 - 5. A composition according to claim 1, being a perfusion solution containing less than 2% by volume of ethanol.
- 10 6. A composition according to claim 5, containing less than 1% by volume of ethanol.
 - 7. A composition according to claim 5, containing less than 0.1% by volume of ethanol.
- 8. A composition according to any one of claims 5 to 7, which is physically stable for at least
 8 hours at room temperature.
 - 69. A cCompositions according to claim 2 or 3any one of claims 2 to 4, characterized in that they contain containing up to 200 mg/ml, and preferably up to 80 mg/ml, of the compounds of formula (I).
 - 10. A composition according to any one of claims 2 to 4, containing up to 80 mg/ml of the compound of formula (I).

20

- 711. A cCompositions according to claim 4any one of claims 2 to 4, characterized in that they
 contain containing 20 to 80 mg/ml of the compounds of formula (I).
 - 8. Compositions according to claim 5, characterized in that they contain 6 to 20 mg/ml of compounds of formula (I).
- 30 12. A composition according to any one of claims 5 to 8, containing up to 1.0 mg/ml of the compound of formula (I).

- 13. A composition according to any one of claims 5 to 8, containing up to 0.5 mg/ml of the compound of formula (I).
- 14. A composition according to any one of claims 5 to 8, containing up to 0.3 mg/ml of the5 compound of formula (I).
 - 15. A composition according to any one of claims 5 to 8, containing up to 0.1 mg/ml of the compound of formula (I).
- 10 16. A composition according to any one of claims 1 to 15, wherein the polysorbate is polysorbate 80.
 - 17. A composition according to any one of claims 5 to 8 or 12 to 16, containing no more than 1.16 %vol of polysorbate.
 - 18. A composition according to any one of claims 5 to 8 or 12 to 16, containing from 0.15 to 0.69 %vol of polysorbate.
- 919. A mMethod for preparing the a compositions according to any one of the preceding claims
 20 2 to 4 or 9 to 11, characterized in that wherein the active principle compound of formula (I) is solubilised in ethanol, the surfactant is added and the ethanol is then evaporated off.
- 4020. A mMethod for preparing the a compositions according to any one of claims 1 to 92 to 4 or 9 to 11, characterized in that wherein the compositions is prepared by slow addition of the active principle compound of formula (I) to a solution of the surfactant containing 1 to 2% ethanol.
 - 1121. A pPerfusion solution, characterized in that it contains containing less than 0.5 mg/ml, and preferably 0.1 to 0.3 mg/ml, of the compound according to claim 4 of formula (I) as defined in claim 1, and in that it contains less than 1 ml/l of ethanol, and less than 15 ml/l of a surfactant which is a polysorbate.
 - 22. The perfusion solution according to claim 21, containing 0.1 to 0.3 mg/ml of the compound of formula (I).

30

15

12. Perfusion, characterized in that it contains 1 mg/ml or less of compound according to claim 5 and in that it contains less than 1 ml/l of ethanol.